A shot in the bone corrects a genetic disease

Molecular Therapy

Volumn 23, Issue 4, 2015, Pages 614-615

  Brown, Brian D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; ELONGATION FACTOR 1ALPHA; GLYCOPROTEIN IB ALPHA; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR;

BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; GENE EXPRESSION; GENE INSERTION; GENE SYNTHESIS; GENE TRANSFER; GENETIC DISORDER; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA A; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; NONHUMAN; NOTE; VIRAL GENE DELIVERY SYSTEM; ADMINISTRATION AND DOSAGE; ANIMAL; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; FACTOR VIII; GENETIC VECTORS; HEMOPHILIA A; HUMANS; LENTIVIRUS;

EID: 84926656449     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.38     Document Type: Note

References (11)

1. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447-458.
2. Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341: 1233158.
3. Naldini, L (2011). Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12: 301-315.
4. Chuah, MK, Evens, H and VandenDriessche, T (2013). Gene therapy for hemophilia. J Thromb Haemost 11 (suppl. 1): 99-110.
5. Moayeri, M, Ramezani, A, Morgan, RA, Hawley, TS and Hawley, RG (2004). Sustained phenotypic correc- tion of hemophilia A mice following oncoretroviralmediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 10: 892-902.
6. Follenzi, A, Raut, S, Merlin, S, Sarkar, R and Gupta, S (2012). Role of bone marrow transplantation for correcting hemophilia A in mice. Blood 119: 5532-5542.
7. Shi, Q, Wilcox, DA, Fahs, SA, Fang, J, Johnson, BD, Du, LM et al. (2007). Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 5: 352-361.
8. Kuether, EL, Schroeder, JA, Fahs, SA, Cooley, BC, Chen, Y, Montgomery, RR et al. (2012). Lentivirusmediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost 10: 1570-1580.
9. Wang, X, Shin, SC, Chiang, AFJ, Khan, I, Pan, D, Rawlings, DJ et al. (2015). Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. Mol Ther 23: 617-626
10. Agudo, J, Ruzo, A, Kitur, K, Sachidanandam, R, Blander, JM and Brown, BD (2012). A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade. Mol Ther 20: 2257-2267.
11. Wang, CX, Sather, BD, Wang, X, Adair, J, Khan, I, Singh, S et al. (2013). Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 124: 913-923.